Skip to main content

About Maxion

Maxion has engineered a new class of biologics by harnessing knottins, one of nature’s most potent modulators of ion channels and G protein-coupled receptors (GPCR). Combining a knottin with an antibody’s advantageous drug properties, we are developing transformative treatments that reach new levels of specificity and durability for patients with ion channel and GPCR-driven diseases. Initially focused on immunological diseases, heart disorders and chronic pain, our pipeline of proprietary KnotBody® molecules will access targets that have long remained beyond the reach of biologics.

Situated at Unity Campus in Cambridge, UK, Maxion Therapeutics fosters a dynamic and forward-thinking work environment underpinned by our scientific founders, who are trailblazers in antibody engineering. Led by our CEO, Dr Arndt Schottelius, our experienced leadership team boasts a stellar track record. Dr Schottelius has held senior leadership positions, successfully advancing therapeutics from research to late-stage clinical development and building valuable portfolios of drug candidates and pharma partnerships. Maxion’s co-founders, Dr John McCafferty (CTO) and Dr Aneesh Karatt Vellatt (CSO), previously co-founded IONTAS, and together invented KnotBody® technology. Dr McCafferty is also renowned for co-inventing antibody phage display, which contributed to the 2018 Nobel Prize in Chemistry (awarded to his co-inventor Sir Gregory Winter), and co-founding Cambridge Antibody Technology.For more information, please visit: https://www.maxiontherapeutics.com/.

About the Role

We are seeking a highly organised and proactive Senior Scientist with deep expertise in human immunology to join our Translational Biology team on a fixed term basis. Reporting to the Director of Translational Biology, the successful candidate will be responsible for developing disease relevant in vitro/ex vivo models and delivering data packages to support MOA studies and indication selection. The ideal candidate will play a key role in our drug discovery efforts and contribute to achieving our ambitious goals. We value individuals who thrive in a dynamic environment and adapt to our agile and fast-paced work culture. 

Application Closing Date:
26 July 2026
Salary:
Competitive